Services
Genomic Testing
Companion Diagnostic Test
Laboratory Developed Tests (LDT)
Solid Tumors
Hematologic Malignancies
Hereditary Cancers
Minimal Residual Disease
Research Services
Platforms
DNA Sequencing
RNA Sequencing
Other Services
Technology
Our Technology
Publications
Partnerships
About Us
What is Precision Oncology?
Our Company
Our Team
Certificates & Accreditation
News
Join Us
Contact Us
Ch|中文
Search
March 9, 2023
Geneseeq and Collaborators Initiate MOTION Study to Evaluate the Performance of Minimal Residual Disease Test SHIELDING™ in Early-stage Lung Cancer
by Geneseeq
January 24, 2023
Geneseeq receives CE Marks for MRD and MCED tests.
by Geneseeq
October 12, 2022
Interesting findings on ctDNA-based MRD detection in patients with resectable non-small cell lung cancer by Geneseeq
by Geneseeq
August 31, 2021
Geneseeq Study Evaluates ctDNA MRD to Predict Response to Therapy and Assess Prognosis in Locally Advanced Rectal Cancer
by Geneseeq
May 18, 2021
Geneseeq study shows ctDNA evaluation in early postoperative phase predicts risk of recurrence in colorectal cancer
by Geneseeq
Privacy Preference Center
Privacy Preferences
